Date: 2014-08-14
Type of information: Nomination
Compound: member of the board of directors
Company: Melinta Therapeutics (USA - CT)
Therapeutic area: Infectious diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On August 14, 2014, Melinta Therapeutics announced the appointment of Christopher Kiritsy to its board of directors. Mr. Kiritsy is currently president, chief executive officer and director of Arisaph Pharmaceuticals, a company he co-founded. Under his leadership, Arisaph has evolved into a clinical development enterprise with a rich research pipeline. His accomplishments include negotiation of multiple business development transactions, which raised approximately $60 million of non-dilutive capital and receipt of a $3 million award from the U.S. government’s Therapeutics Discovery Project Program. Prior to Arisaph, Mr. Kiritsy served as executive vice president, corporate development and chief financial officer of Kos Pharmaceuticals, where he executed Kos’ IPO, raised approximately $500 million in public equity, and spearheaded more than 10 major corporate development transactions. He has also served as associate director of product development at the Institute of Molecular Biology, a private biotechnology company, where he co-authored several scientific publications.
- Christopher Kiritsy is also currently serving as chairman of the Board of Directors of Avaxia Biologics, a private biotechnology company developing orally administered, minimally absorbed antibody therapeutics for gastrointestinal disorders.
Financial terms:
Latest news:
Is general: Yes
